BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 12648066)

  • 1. Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma.
    Chau I; Harries M; Cunningham D; Hill M; Ross PJ; Archer CD; Norman AR; Wotherspoon A; Koh DM; Gill K; Uzzell M; Prior Y; Catovsky D
    Br J Haematol; 2003 Mar; 120(6):970-7. PubMed ID: 12648066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R-GEM-P) is an effective regimen in relapsed diffuse large B-cell lymphoma.
    Barton S; Hawkes EA; Cunningham D; Peckitt C; Chua S; Wotherspoon A; Attygalle A; Horwich A; Potter M; Ethell M; Dearden C; Gleeson M; Chau I
    Eur J Haematol; 2015 Mar; 94(3):219-26. PubMed ID: 25039915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma.
    Ng M; Waters J; Cunningham D; Chau I; Horwich A; Hill M; Norman AR; Wotherspoon A; Catovsky D
    Br J Cancer; 2005 Apr; 92(8):1352-7. PubMed ID: 15812553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pilot study of fixed-infusion rate gemcitabine with Cisplatin and dexamethasone in patients with relapsed or refractory lymphoma.
    Emmanouilides C; Colovos C; Pinter-Brown L; Hernandez L; Schiller G; Territo M; Rosen P
    Clin Lymphoma; 2004 Jun; 5(1):45-9. PubMed ID: 15245607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study.
    Corazzelli G; Russo F; Capobianco G; Marcacci G; Della Cioppa P; Pinto A
    Ann Oncol; 2006 May; 17 Suppl 4():iv18-24. PubMed ID: 16702180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
    Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
    Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma.
    Hawkes EA; Barton S; Cunningham D; Peckitt C; Chua S; Wotherspoon A; Horwich A; Potter M; Ethel M; Dearden C; Chau I
    Ann Hematol; 2014 May; 93(5):827-34. PubMed ID: 24158386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma.
    Dumontet C; Morschhauser F; Solal-Celigny P; Bouafia F; Bourgeois E; Thieblemont C; Leleu X; Hequet O; Salles G; Coiffier B
    Br J Haematol; 2001 Jun; 113(3):772-8. PubMed ID: 11380469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine, cisplatin and methylprednisolone (GEM-P) with or without Rituximab in relapsed and refractory patients with diffuse large B cell lymphoma (DLBCL).
    Sirohi B; Cunningham D; Norman A; Last K; Chau I; Horwich A; Oates J; Chong G; Wotherspoon A
    Hematology; 2007 Apr; 12(2):149-53. PubMed ID: 17454196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma.
    Chau I; Webb A; Cunningham D; Hill M; Rao S; Ageli S; Norman A; Gill K; Howard A; Catovsky D
    Br J Haematol; 2001 Dec; 115(4):786-92. PubMed ID: 11843810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab, gemcitabine, cisplatin, and dexamethasone in patients with refractory or relapsed aggressive B-cell lymphoma.
    Hou Y; Wang HQ; Ba Y
    Med Oncol; 2012 Dec; 29(4):2409-16. PubMed ID: 22476761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma.
    Lim ST; Fayad L; Tulpule A; Modiano M; Cabanillas F; Laffranchi B; Allievi C; Bernareggi A; Levine AM
    Leuk Lymphoma; 2007 Feb; 48(2):374-80. PubMed ID: 17325899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine, etoposide, cisplatin, and dexamethasone in patients with refractory or relapsed non-Hodgkin's lymphoma.
    Kim KH; Joo YD; Sohn CH; Shin HJ; Chung JS; Cho GJ; Shin SH; Kim YS; Lee WS
    Korean J Intern Med; 2009 Mar; 24(1):37-42. PubMed ID: 19270480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial.
    Cole PD; McCarten KM; Pei Q; Spira M; Metzger ML; Drachtman RA; Horton TM; Bush R; Blaney SM; Weigel BJ; Kelly KM
    Lancet Oncol; 2018 Sep; 19(9):1229-1238. PubMed ID: 30122620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of gemcitabine, cisplatin and methylprednisolone (GEM-P) combination treatment for non-Hodgkin T cell lymphoma.
    Yim KL; Ashley S
    Med Oncol; 2012 Dec; 29(5):3535-9. PubMed ID: 22825684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
    O'Connor OA; Lue JK; Sawas A; Amengual JE; Deng C; Kalac M; Falchi L; Marchi E; Turenne I; Lichtenstein R; Rojas C; Francescone M; Schwartz L; Cheng B; Savage KJ; Villa D; Crump M; Prica A; Kukreti V; Cremers S; Connors JM; Kuruvilla J
    Lancet Oncol; 2018 Feb; 19(2):257-266. PubMed ID: 29276022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive non-Hodgkin's Lymphoma: a report of 24 cases].
    Fan Y; Huang ZY; Luo LH; Yu HF
    Ai Zheng; 2008 Nov; 27(11):1222-5. PubMed ID: 19000458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma.
    Hänel M; Kröger N; Kroschinsky F; Birkmann J; Hänel A; Herbst R; Naumann R; Friedrichsen K; Ehninger G; Zander AR; Fiedler F
    J Cancer Res Clin Oncol; 2001; 127(6):387-95. PubMed ID: 11414199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine and treatment of diffuse large B-cell lymphoma in relapsed or refractory elderly patients: a prospective randomized trial in Algeria.
    Aribi M; Mesli N; Remla N; Sari BE; Taleb A; Touhami H; Bekadja MA; Zouaoui-Benhadji Z; Bouzid K; Meguenni K
    J Cancer Res Ther; 2010; 6(1):41-6. PubMed ID: 20479546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy and safety evaluation of gemcitabine combined with oxaliplatin in lymphoma patients after failure of multiple chemotherapy regimens].
    Yang J; Shi Y; He X; Zhou S; Dong M; Liu P; Zhang C; Qin Y; Yang S; Gui L
    Zhonghua Zhong Liu Za Zhi; 2014 Feb; 36(2):137-40. PubMed ID: 24796464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.